GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Phase ⅠStudy of GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid Tumors
Sponsor: Chinese PLA General Hospital
This PHASE1 trial investigates Hematologic Malignancy and Solid Tumor and is currently completed. Chinese PLA General Hospital leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2022 — Jan 2024 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese PLA General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .